Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders
Mycobacterial Infections can be severe in patients with T-cell deficiency or phagocyte disorders, and treatment is frequently complicated by antimicrobial resistance. Restoration of T-cell immunity via stem cell transplantation facilitates control of mycobacterial infections, but presence of active...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.00621/full |
id |
doaj-537ffc6a02874c9180d3ffe55bd51802 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shabnum Patel Shabnum Patel Haili Lang Gelina Sani Alexandra F. Freeman Jennifer Leiding Jennifer Leiding Jennifer Leiding Patrick J. Hanley Patrick J. Hanley Conrad Russell Cruz Conrad Russell Cruz Melanie Grant Yunfei Wang Benjamin Oshrine Cindy Palmer Steven M. Holland Catherine M. Bollard Catherine M. Bollard Catherine M. Bollard Michael D. Keller Michael D. Keller |
spellingShingle |
Shabnum Patel Shabnum Patel Haili Lang Gelina Sani Alexandra F. Freeman Jennifer Leiding Jennifer Leiding Jennifer Leiding Patrick J. Hanley Patrick J. Hanley Conrad Russell Cruz Conrad Russell Cruz Melanie Grant Yunfei Wang Benjamin Oshrine Cindy Palmer Steven M. Holland Catherine M. Bollard Catherine M. Bollard Catherine M. Bollard Michael D. Keller Michael D. Keller Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders Frontiers in Immunology immunotherapy T cells mycobacteria primary immunodeficiency mendelian suspectibility to mycobacteria hematopoietic stem cell transplantation |
author_facet |
Shabnum Patel Shabnum Patel Haili Lang Gelina Sani Alexandra F. Freeman Jennifer Leiding Jennifer Leiding Jennifer Leiding Patrick J. Hanley Patrick J. Hanley Conrad Russell Cruz Conrad Russell Cruz Melanie Grant Yunfei Wang Benjamin Oshrine Cindy Palmer Steven M. Holland Catherine M. Bollard Catherine M. Bollard Catherine M. Bollard Michael D. Keller Michael D. Keller |
author_sort |
Shabnum Patel |
title |
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders |
title_short |
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders |
title_full |
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders |
title_fullStr |
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders |
title_full_unstemmed |
Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders |
title_sort |
mycobacteria-specific t cells may be expanded from healthy donors and are near absent in primary immunodeficiency disorders |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2019-03-01 |
description |
Mycobacterial Infections can be severe in patients with T-cell deficiency or phagocyte disorders, and treatment is frequently complicated by antimicrobial resistance. Restoration of T-cell immunity via stem cell transplantation facilitates control of mycobacterial infections, but presence of active infections during transplantation is associated with a higher risk of mortality. Adoptive T cell immunotherapy has been successful in targeting viruses, but has not been attempted to treat mycobacterial infections. We sought to expand and characterize mycobacterial-specific T-cells derived from healthy donors in order to determine suitability for adoptive immunotherapy. Mycobacteria-specific T-cells (MSTs) were generated from 10 healthy donors using a rapid ex vivo expansion protocol targeting five known mycobacterial target proteins (AG85B, PPE68, ESXA, ESXB, and ADK). MSTs were compared to T-cells expanded from the same donors using lysate from M. tuberculosis or purified protein derivative from M. avium (sensitin). MST expansion from seven patients with primary immunodeficiency disorders (PID) and two patients with IFN-γ autoantibodies and invasive M. avium infections. MSTs expanded from healthy donors recognized a median of 3 of 5 antigens, with production of IFN-γ, TNF, and GM-CSF in CD4+ T cells. Comparison of donors who received BCG vaccine (n = 6) to those who did not (n = 4) showed differential responses to PPE68 (p = 0.028) and ADK (p = 0.015) by IFN-γ ELISpot. MSTs expanded from lysate or sensitin also recognized multiple mycobacterial antigens, with a statistically significant differences noted only in the response to PPE68 (p = 0.016). MSTs expanded from patients with primary immunodeficiency (PID) and invasive mycobacterial infections showed activity against mycobacterial antigens in only two of seven subjects, whereas both patients with IFN-γ autoantibodies recognized mycobacterial antigens. Thus, MSTs can be generated from donors using a rapid expansion protocol regardless of history of BCG immunization. Most tested PID patients had no detectable T-cell immunity to mycobacteria despite history of infection. MSTs may have clinical utility for adoptive immunotherapy in T-cell deficient patients with invasive mycobacterial infections. |
topic |
immunotherapy T cells mycobacteria primary immunodeficiency mendelian suspectibility to mycobacteria hematopoietic stem cell transplantation |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.00621/full |
work_keys_str_mv |
AT shabnumpatel mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT shabnumpatel mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT haililang mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT gelinasani mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT alexandraffreeman mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT jenniferleiding mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT jenniferleiding mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT jenniferleiding mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT patrickjhanley mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT patrickjhanley mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT conradrussellcruz mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT conradrussellcruz mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT melaniegrant mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT yunfeiwang mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT benjaminoshrine mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT cindypalmer mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT stevenmholland mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT catherinembollard mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT catherinembollard mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT catherinembollard mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT michaeldkeller mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders AT michaeldkeller mycobacteriaspecifictcellsmaybeexpandedfromhealthydonorsandarenearabsentinprimaryimmunodeficiencydisorders |
_version_ |
1725238819554328576 |
spelling |
doaj-537ffc6a02874c9180d3ffe55bd518022020-11-25T00:53:12ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-03-011010.3389/fimmu.2019.00621442314Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency DisordersShabnum Patel0Shabnum Patel1Haili Lang2Gelina Sani3Alexandra F. Freeman4Jennifer Leiding5Jennifer Leiding6Jennifer Leiding7Patrick J. Hanley8Patrick J. Hanley9Conrad Russell Cruz10Conrad Russell Cruz11Melanie Grant12Yunfei Wang13Benjamin Oshrine14Cindy Palmer15Steven M. Holland16Catherine M. Bollard17Catherine M. Bollard18Catherine M. Bollard19Michael D. Keller20Michael D. Keller21Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesGW Cancer Center, George Washington University, Washington, DC, United StatesCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesLaboratory of Clinical Immunology and Microbiology, NIAID, National Institutes of Health, Bethesda, MD, United StatesDivision of Allergy & Immunology, University of South Florida, St. Petersburg, FL, United StatesDepartment of Pediatrics, University of South Florida, St. Petersburg, FL, United StatesCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, FL, United StatesCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesDivision of Blood and Marrow Transplantation, Children's National Health System, Washington, DC, United StatesCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesGW Cancer Center, George Washington University, Washington, DC, United StatesCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesClinical and Translational Science Institute, Children's National Health System, Washington, DC, United StatesCancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, FL, United StatesLaboratory of Clinical Immunology and Microbiology, NIAID, National Institutes of Health, Bethesda, MD, United StatesLaboratory of Clinical Immunology and Microbiology, NIAID, National Institutes of Health, Bethesda, MD, United StatesCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesGW Cancer Center, George Washington University, Washington, DC, United StatesDivision of Blood and Marrow Transplantation, Children's National Health System, Washington, DC, United StatesCenter for Cancer and Immunology Research, Children's National Health System, Washington, DC, United StatesDivision of Allergy & Immunology, Children's National Health System, Washington, DC, United StatesMycobacterial Infections can be severe in patients with T-cell deficiency or phagocyte disorders, and treatment is frequently complicated by antimicrobial resistance. Restoration of T-cell immunity via stem cell transplantation facilitates control of mycobacterial infections, but presence of active infections during transplantation is associated with a higher risk of mortality. Adoptive T cell immunotherapy has been successful in targeting viruses, but has not been attempted to treat mycobacterial infections. We sought to expand and characterize mycobacterial-specific T-cells derived from healthy donors in order to determine suitability for adoptive immunotherapy. Mycobacteria-specific T-cells (MSTs) were generated from 10 healthy donors using a rapid ex vivo expansion protocol targeting five known mycobacterial target proteins (AG85B, PPE68, ESXA, ESXB, and ADK). MSTs were compared to T-cells expanded from the same donors using lysate from M. tuberculosis or purified protein derivative from M. avium (sensitin). MST expansion from seven patients with primary immunodeficiency disorders (PID) and two patients with IFN-γ autoantibodies and invasive M. avium infections. MSTs expanded from healthy donors recognized a median of 3 of 5 antigens, with production of IFN-γ, TNF, and GM-CSF in CD4+ T cells. Comparison of donors who received BCG vaccine (n = 6) to those who did not (n = 4) showed differential responses to PPE68 (p = 0.028) and ADK (p = 0.015) by IFN-γ ELISpot. MSTs expanded from lysate or sensitin also recognized multiple mycobacterial antigens, with a statistically significant differences noted only in the response to PPE68 (p = 0.016). MSTs expanded from patients with primary immunodeficiency (PID) and invasive mycobacterial infections showed activity against mycobacterial antigens in only two of seven subjects, whereas both patients with IFN-γ autoantibodies recognized mycobacterial antigens. Thus, MSTs can be generated from donors using a rapid expansion protocol regardless of history of BCG immunization. Most tested PID patients had no detectable T-cell immunity to mycobacteria despite history of infection. MSTs may have clinical utility for adoptive immunotherapy in T-cell deficient patients with invasive mycobacterial infections.https://www.frontiersin.org/article/10.3389/fimmu.2019.00621/fullimmunotherapyT cellsmycobacteriaprimary immunodeficiencymendelian suspectibility to mycobacteriahematopoietic stem cell transplantation |